Visus, with one drug chasing AbbVie, inks deals to grow pipeline

Visus Therapeutics is moving quickly to establish itself in the ophthalmic therapy space. Days after raising $20 million to fuel its pursuit of AbbVie in one indication, Visus has disclosed two deals that add to its R&D options.